May 19, 2008 -- Tibotec Therapeutics today announced the availability of a new 600 mg tablet strength for Prezista (darunavir), a protease inhibitor (PI). The new dosage strength was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2008. The recommended oral dose of PREZISTA for treatment-experienced adult patients with HIV-1 is 600 mg (one 600 mg tablet or two 300 mg tablets) taken twice daily with ritonavir 100 mg, in combination with other antiretroviral agents, and with food.
The details can be read here.
No comments:
Post a Comment